Cannabix Technologies Granted Patent from USPTO for Contactless Breath Analysis

Executive Summary

• The United States Patent and Trademark Office granted Cannabix Technologies Inc. U.S. Patent No. 18/1729,658 for its “Contact‑Free Breath Analysis Device and Method.”
• The patented technology underpins the company’s BreathLogix platform, enabling dual‑mode (contactless and traditional mouthpiece) breath capture for alcohol and THC detection in workplaces, law enforcement, vehicles, and public kiosks.
• CEO Rav Mlait highlighted the grant as a significant addition to Cannabix’s patent portfolio, reinforcing its leadership in breath sampling and detection technologies.

Key Details

• Patent Information: U.S. Patent No. 18/1729,658 titled “Contact‑Free Breath Analysis Device and Method.”
• Technology Scope: Dual‑mode contactless and mouthpiece breath capture; real‑time feedback via visual indicators; automatic airflow and pump adjustment for accurate, hygienic analysis.
• Potential Applications: Integration into vehicles, workplaces, public kiosks; use in unmanned breath devices; law enforcement, workplace safety, and public health monitoring.
• Device Platform: The patented innovations are incorporated into Cannabix’s BreathLogix device platform (see Figure 1).
• CEO Quote: “We are very pleased to add this important innovation to our patent portfolio. This patent grant enhances Cannabix’s leadership in the world of breath sampling and detection techniques.” – Rav Mlait, CEO.

Notable Quotes

“We are very pleased to add this important innovation to our patent portfolio. This patent grant enhances Cannabix’s leadership in the world of breath sampling and detection techniques.” – Rav Mlait, CEO, Cannabix Technologies Inc.